Search results
The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring
Investor's Business Daily· 6 months agoBiotech stock Xenon Pharmaceuticals rocketed Monday, overtaking its 50-day moving average, after its...
Xenon Pharmaceuticals' (NASDAQ:XENE) investors will be pleased with their enviable 884% return over...
Simply Wall St. via Yahoo Finance· 2 years agoWe think all investors should try to buy and hold high quality multi-year winners. And we've seen...
Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All
Investor's Business Daily· 2 years agoXenon Pharmaceuticals announced a $250 million public offering following positive test results for a...
Xenon drug misses main goal of depression study
BioPharma Dive via Yahoo Finance· 6 months agoYet, the company believes there were enough positive findings in the mid-stage trial to warrant further study of its drug, called XEN1101, in depression.
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
Zacks via Yahoo Finance· 6 months agoXenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline...
‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks
TipRanks via Yahoo Finance· 9 months agoThe markets have experienced a period of volatility over the past month, raising questions about...
Morning News Call - Canada, November 7
Reuters via Yahoo Finance· 2 years agoTo access a PDF version of this newsletter, please click here You can read Morning News Call Canada via TOPNEWS Canada page. If you would like to receive this newsletter through your email, ...
